| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 04/12/2011 | CA2488775C Fcyriia transgenic animal model for autoimmune disease |
| 04/12/2011 | CA2458035C Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them |
| 04/12/2011 | CA2456172C Kidney-specific urate transporter and uses thereof |
| 04/12/2011 | CA2426461C Nitrogen-containing aromatic derivatives |
| 04/12/2011 | CA2388363C Dna polymerase lambda and uses thereof |
| 04/07/2011 | WO2011041599A2 6-methylvitamin d3 analogs and their uses |
| 04/07/2011 | WO2011041590A2 1-desoxy-2-methylene-19-nor-vitamin d analogs and their uses |
| 04/07/2011 | WO2011040823A1 Synthetic myostatin peptide antagonists |
| 04/07/2011 | WO2011040449A1 Novel phenol derivative |
| 04/07/2011 | WO2011039338A2 Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
| 04/07/2011 | WO2011038579A1 Compounds and compositions as protein kinase inhibitors |
| 04/07/2011 | US20110082407 Combination Therapies for the Treatment of Obesity |
| 04/07/2011 | US20110082213 Novel salts of o-desmethyl-venlafaxine |
| 04/07/2011 | US20110082209 Novel Salts of (4--2-Methylphenyl)Carbonyl]Amino}-3-Methylphenyl)Acetic Acid |
| 04/07/2011 | US20110082206 Heteroatom containing substituted fatty acids |
| 04/07/2011 | US20110082200 5,6,7-trihydroxyheptanoic acid and analogs for the treatment of ocular diseases and diseases associated with hyperproliferative and angiogenic responses |
| 04/07/2011 | US20110082199 Use of non-toxic crosslinking reagents to improve fatigue resistance and reduce mechanical degradation of intervertebral disc and other collagenous tissues |
| 04/07/2011 | US20110082197 Method for inhibiting formation and/or activation of osteoclasts using flemingia macrophylla extract or lespedeza flavanone A |
| 04/07/2011 | US20110082192 Lipoic acid acylated salicylate derivatives and their uses |
| 04/07/2011 | US20110082178 Methods of treating autoimmune and inflammatory diseases and disorders |
| 04/07/2011 | US20110082166 Novel 4-benzhydryl-tetrahydro-pyridine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 04/07/2011 | US20110082149 Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation |
| 04/07/2011 | US20110082142 Selective kinase inhibitors |
| 04/07/2011 | US20110082141 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| 04/07/2011 | US20110082131 Triazole derivatives useful as axl inhibitors |
| 04/07/2011 | US20110082123 6-Methylvitamin D3 Analogs and Their Uses |
| 04/07/2011 | US20110082121 1-Desoxy-2-Methylene-19-Nor-Vitamin D Analogs and Their Uses |
| 04/07/2011 | US20110082113 Prodrugs of a piperidinyl derivative as modulators of chemokine receptor activity |
| 04/07/2011 | US20110082107 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 |
| 04/07/2011 | US20110082086 Medicament for use in connection with cartilage impairment |
| 04/07/2011 | US20110082081 Compositions and methods for repair of tissues |
| 04/07/2011 | US20110081428 Use of thioflavin-like compounds to increase life span and/or health span |
| 04/07/2011 | US20110081424 Nutritional composition for bariatric surgery patients |
| 04/07/2011 | US20110081417 Surgical compositions |
| 04/07/2011 | US20110081410 Therapeutic agent for local inflammation |
| 04/07/2011 | US20110081409 Selective inhibitors of histone deacetylase |
| 04/07/2011 | US20110081396 Glass ceramic scaffolds with complex topography |
| 04/07/2011 | US20110081369 Immune modulation with death receptor-induced apoptosis |
| 04/07/2011 | US20110081366 Immunostimulatory nucleic acid molecules |
| 04/07/2011 | US20110081364 Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases |
| 04/07/2011 | US20110081361 Antibodies that bind interleukin-4 receptor |
| 04/07/2011 | US20110081355 Methods of Diagnosing and Treating Conditions Using Anti-IL-6 Antibodies |
| 04/07/2011 | US20110081340 Methods for treating disease using an anti-il-21 receptor antibody |
| 04/07/2011 | US20110081339 Methods of using il-17 receptor a antibodies |
| 04/07/2011 | US20110081338 Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation |
| 04/07/2011 | US20110081337 Function of gpr4 in vascular inflammatory response to acidosis and related methods |
| 04/07/2011 | US20110081324 Collagen peptide conjugates and uses therefor |
| 04/07/2011 | US20110081323 Methods and compositions for organ and tissue functionality |
| 04/07/2011 | US20110081320 Treatment/Cure of Autoimmune Disease |
| 04/07/2011 | US20110081319 Composition and use of phyto-percolate for treatment of disease |
| 04/07/2011 | CA2776529A1 Synthetic myostatin peptide antagonists |
| 04/07/2011 | CA2775309A1 Novel phenol derivative |
| 04/07/2011 | CA2774903A1 Use of compounds with sglt-1/sglt-2 inhibitor activity for producing medicaments for treatment of bone diseases |
| 04/06/2011 | EP2305819A1 Conjugates prepared with aggregate-free proteins |
| 04/06/2011 | EP2305810A1 miRNAs in the treatment of fibrosis |
| 04/06/2011 | EP2305715A2 Monoclonal antibody to osteoprotegerin binding protein |
| 04/06/2011 | EP2305713A1 Human antibodies that bind human TNFalpha |
| 04/06/2011 | EP2305712A1 Human antibodies that bind human TNFalpha |
| 04/06/2011 | EP2305711A2 Methods for treating osteoarthitis pain by administering a nerve growth factor antagonist and compositions containing the same |
| 04/06/2011 | EP2305694A2 Novel anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
| 04/06/2011 | EP2305677A1 Alkyne-aryl-naphthyridin-4(1h)-one derivatives as type IV phosphodiesterase inhibitor |
| 04/06/2011 | EP2305663A1 Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels |
| 04/06/2011 | EP2305314A2 Remodelling and glycoconjugation of antibodies |
| 04/06/2011 | EP2305313A2 Remodelling and glycoconjugation of interferon-alpha (IFNa) |
| 04/06/2011 | EP2305312A2 Remodelling and glycoconjugation of follicle-stimulating hormone (FSH) |
| 04/06/2011 | EP2305311A2 Glycoconjugation of peptides |
| 04/06/2011 | EP2305305A1 Agent for induction/maintenance of remission |
| 04/06/2011 | EP2305276A2 Processed lipoaspirate cells for use in therapy |
| 04/06/2011 | EP2305268A1 A pharmaceutical composition for treating disease caused by immune disturbance and the extract from tuckahoe |
| 04/06/2011 | EP2305248A1 Substituted phenethylsulfones and method of reducing tnf-alpha levels |
| 04/06/2011 | EP2305233A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 04/06/2011 | EP2305232A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 04/06/2011 | EP2305231A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases |
| 04/06/2011 | EP2305223A1 Agent for activating stem cells |
| 04/06/2011 | EP2305213A2 The treatment of small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions |
| 04/06/2011 | EP2303930A1 A sulfated polysaccharide compound and the preparation and use thereof |
| 04/06/2011 | EP2303336A2 Sulfonylurea receptor and means for treating ischaemia |
| 04/06/2011 | EP2303306A2 Development of a c-reactive protein mutant with improved therapeutic benefit in immune thrombocytopenia and lupus nephritis |
| 04/06/2011 | EP2303302A2 A formulation and method for relieving or preventing symptoms associated with uric acid crystals |
| 04/06/2011 | EP2303290A1 Repair and/or reconstitution of invertebral discs |
| 04/06/2011 | EP2303279A1 Topical steroidal formulations |
| 04/06/2011 | EP2303278A1 Composition for modulating stem cell growth with prostaglandins |
| 04/06/2011 | EP2303268A1 Pharmaceutical compositions based on kinin b2 receptor antagonists and corticosteroids, and their use |
| 04/06/2011 | EP2303261A1 Use of cyclolignans for the treatment of a hyperactive immune system |
| 04/06/2011 | EP2303249A2 Anthraquinones and analogs from rhuem palmatum for treatment of estrogen receptor beta-mediated conditions |
| 04/06/2011 | EP2303231A1 Preparation containing glucosamine and/or chondroitin for prophylaxis and treatment of arthrosis and for supporting the immune system |
| 04/06/2011 | EP2046787B1 Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| 04/06/2011 | EP1628968B1 4-imidazolin-2-one compounds |
| 04/06/2011 | EP1594889B1 Nell peptide expression systems and bone formation activity of nell peptide |
| 04/06/2011 | EP1519939B9 N-aryl diazaspirocyclic compounds and methods of preparation and use thereof |
| 04/06/2011 | EP1404324B2 Prodrugs of gaba analogs, compositions and uses thereof |
| 04/06/2011 | EP1303522B1 Biologically active macrolides, compositions, and uses thereof |
| 04/06/2011 | CN1970547B Novel febuxostat crystal form and its preparation method |
| 04/06/2011 | CN1931277B Osteoarthrosis treating Chinese medicine composition and its preparation process |
| 04/06/2011 | CN1730476B Aromatic amine ketone compounds, its synthesis method, pharmaceutical composition containing same and uses |
| 04/06/2011 | CN1658893B G-type peptides to ameliorate atherosclerosis |
| 04/06/2011 | CN1376146B Solid-state form of celecoxil having enhanced bioavailability |
| 04/06/2011 | CN102007110A Novel flavonol compounds, a bioactive extract/fraction from ulmus wallichiana and its compounds for prevention for treatment of osteo-health related disorders |
| 04/06/2011 | CN102002493A Application of small RNA-326 in preparation of medicament |
| 04/06/2011 | CN102000342A Preparation method of superparamagnetism conductive nano gamma-ferric oxide/ polyaniline-dexamethasone sodium phosphate |